DKDiana E. Kaurova

Diana E. Kaurova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Diana E. Kaurova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Ivan N. Myasnyanko

    Laboratory of Medicinal Substances Chemistry, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Ostrovitianova 1, Moscow 117513, Russia

    5 shared publications
  • Mikhail S. Baranov

    Laboratory of Medicinal Substances Chemistry, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Ostrovitianova 1, Moscow 117513, Russia

    5 shared publications
  • Nikita S. Popov

    Tver State Medical University

    5 shared publications
  • Vadim Yur'EVich Balabaniyan

    N.I. Pirogov Russian National Research Medical University

    5 shared publications
  • Dmitry A. Gavrilenko

    Tver State Medical University

    4 shared publications
  • В. Ю. Балабаньян

    Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России)

    3 shared publications

Latest Publications

  • Open Access

    Pharmacokinetics and Effect of Novel Sydnonimine on NO and cGMP Accumulation In Vivo

    by Nikita S. Popov, Dmitry A. Gavrilenko, Dmitry O. Tsypyshev, Vladimir V. Turovtsev, Mikhail S. Baranov, Dmitry S. Ivanov, Ivan N. Myasnyanko, Diana E. Kaurova, Sergey A. Filatov, Yulia V. Vakhitova, et al.

    Background: Sydnonimines are mesoionic heterocyclic NO donors with vasodilatory activity. Molsidomine, a clinically approved sydnonimine, has limited blood–brain barrier (BBB) penetration, restricting its use for cerebrovascular disorders. This study characterizes the lead compound BBP2023 as a potential NO donor with putative cerebral action. Methods: In silico ADME profiling (RDKit) of 14 sydnonimines, rat pharmacokinetics of oral BBP2023 (11 mg/kg) vs. molsidomine (10.4 mg/kg), HPLC-MS/MS of NO/cGMP, and docking against four human sGC PDB entries were performed. Results: BBP2023 showed high lipophilicity (logP 1.58), low TPSA (69.78 Å2) and predicted high BBB permeability. After oral dosing, BBP2023 was rapidly absorbed (plasma Tmax 0.17 h, Cmax 389 ng/mL, AUC_last 235 h·ng/mL) and extensively distributed, with highest exposure in liver (AUC_last 1457 h·ng/mL, ~6-fold plasma), indicating primary hepatic metabolism. Brain penetration was confirmed (fr = 1.39, MRT 3.01 h). The active metabolite BBP2023 A appeared later (plasma Tmax 1.00 h, Cmax 22 ng/mL) and accumulated in the lungs (fr = 25.31, AUC_last 1569 h·ng/mL) and brain (fr = 3.65, MRT 4.16 h). Compared with molsidomine, BBP2023 achieved higher brain exposure (availability 1.4 vs. 0.2, Cmax 852.5 vs. 142.3 pmol/mL) and faster brain Tmax (≤0.25 h vs. 1 h). BBP2023 significantly increased NO and cGMP in the brain (131.00 ± 26.39 nM/g and 1070.83 ± 92.04 pM/g, respectively), whereas molsidomine predominantly elevated heart NO. Docking and MM-GBSA calculations suggested possible interactions of BBP2023 and its metabolites with the sGC stimulator site and associated the intact sydnonimine ring with more favorable calculated scores. Conclusions: BBP2023 acts as a NO donor with favorable pharmacokinetics, effective BBB penetration, and brain NO/cGMP accumulation, supporting its further development for cerebrovascular disorders.

  • Open Access

    Development and validation of HPLC-MS/MS technique for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit plasma

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, D. E. Kaurova, I. N. Myasnyanko, I. A. Solokha, V. Yu. Balabanyan, В. Ю. Балабаньян

    Introduction. BBP2023 is a new drug candidate of the sydnonymine group with cerebral vasodilating activity and procognitive properties. The pharmacological effects of BBP2023 are due to the presence of active metabolites. To conduct pharmacokinetic studies at the preclinical stage, it is necessary to develop a bioanalytical method for the determination of BBP2023 and its metabolites in rabbit blood plasma. Aim. Development and validation of a chromatography-mass spectrometric method for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit blood plasma. Materials and methods. Quantitative determination of BBP2023 in rabbit blood plasma was performed by HPLC-MS/MS. The biomaterial sample preparation was based on the method of protein precipitation with methanol. Chromatographic separation was performed with a mixture of deionized water and acetonitrile in a gradient mode on a ZORBAX Eclipse XDB-C18 analytical column (4.6 × 50 mm, 5 μm) using an Agilent 1260 Infinity II chromatograph. Detection was performed in the MRM mode using an AB Sciex QTRAP 3200 MD mass spectrometer. N-(ethoxycarbonyl)-3-(4-methylpentan-2-yl)sydnonymine was used as the internal standard. Results and discussion. The method for sample preparation of rabbit blood plasma has been developed, optimal conditions for chromatography and detection of the studied compound and its metabolites have been selected. The bioanalytical method has been validated according to the following parameters: selectivity, matrix effect, recovery rate, carry-over effect, linearity of the calibration range, lower limit of quantitative determination, intraand inter-run accuracy and precision, as well as stability of analytes and the internal standard at the analysis stages. Conclusion. A method for the quantitative determination of a new derivative of sydnonymine BBP2023 and its metabolites in rabbit blood plasma using HPLC-MS/MS has been developed and validated. The confirmed analytical ranges for BBP2023, BBP2023 A and BBP2023 C were 5.0–500.0 ng/ml (5.0–1000.0 ng/ml for geranamine). The method was used in the analytical part of the preclinical pharmacokinetic study of BBP2023 in rabbits.

  • Open Access

    Study of the pharmacokinetics of a new sidnonymine derivative in mice with intragastric administration

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, D. S. Kaurova, I. N. Myasnyanko, D. S. Ivanov, I. Yu. Ilnitskaya, V. Yu. Balabanyan, В. Ю. Балабаньян

    Relevance. BBP2023 is a new drug candidate of the sydnonimine group, possessing predominantly central vasodilating activity. Objective. To study the pharmacokinetics of the drug candidate BBP2023 in mice after intragastric administration, including an assessment of distribution to organs and tissues. Materials and methods. Experiments were performed on 102 outbred male mice. The animals received a single intragastric dose of BBP2023 at 22.0 mg/kg as an oil emulsion. The total duration of the experiment was 72 hours, during which the animals were euthanized by decapitation at specific time points. Plasma was obtained from blood; homogenates were prepared from internal organs (liver, kidneys, heart, lungs, brain, spleen, muscles, omentum). These were analyzed for the quantitative content of BBP2023 and its metabolites using a previously developed and validated HPLC-MS/MS method. The main pharmacokinetic parameters were calculated using a non-compartmental method. Results. After intragastric administration, BBP2023 was detected in all studied organs and tissues. The time to reach the maximum concentration (0.58 μg/ml) in plasma was 15 minutes, and the elimination half-life was about 7.9 hours. The highest distribution found was to the liver (fr = 2.83), lungs (fr = 1.58), and omentum (fr = 2.62). The minimum value of the elimination rate constant, excluding blood plasma, was observed in brain tissues. The active metabolite BBP2023 A was primarily localized in the kidneys (fr = 16.85) and liver (fr = 4.61). The time to reach the maximum concentration in all organs and tissues ranged from 15 to 45 minutes. Conclusion. The results of the study established that the sydnonimine group drug candidate BBP2023, as well as its active metabolite (BBP2023 A), are detected in mouse brain tissues, which contributes to the realization of cerebral vasodilating activity.


  • Open Access

    Study of the pharmacokinetics of a new sidnonymine derivative in rabbits with various routes of administration

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, D. E. Kaurova, I. N. Myasnyanko, V. Yu. Balabanyan, В. Ю. Балабаньян

    Relevance. The search for vasodilating agents that predominantly accumulate in brain tissues is an urgent task. One of the drug candidates with cerebral vasodilating activity is BBP2023 a derivative of sydnonymine. Objective. A comparative assessment of the pharmacokinetics of BBP2023 in rabbits after a single administration via different routes. Methods. Experiments were performed using a crossover design on 8 rabbits. The rabbits received a single dose of BBP2023 at 2.0 mg/kg as an oil emulsion intragastrically and rectally, and as an aqueous DMSO solution intravenously and intramuscularly. Blood samples were collected from the marginal ear vein at specific time points. The quantitative determination of BBP2023 and its metabolites in blood plasma was performed using HPLC-MS/MS. Results. It was found that the highest bioavailability values are achieved with intramuscular administration (97.4 %). With intragastric and rectal administration, this indicator averaged 46.1 and 15.3 %, respectively. The maximum concentration of BBP2023 in blood plasma is reached on average 5 minutes after intragastric administration and averages 0.620 μg/ml; the half-life value averages 1 hour. The maximum concentration of the active metabolite BBP2023 A in blood plasma after intragastric administration is detected on average after 25 minutes and is 0.076 μg/ml. Conclusion. The pharmacokinetics of the active pharmaceutical substance of drug candidate BBP2023 was studied in rabbits. The results obtained were used for the subsequent selection of the optimal finished dosage form and route of administration.


  • Open Access

    Study of the biotransformation of a new sydnonimine derivative with predominant cerebral vasodilatory activity

    by Nikita S. Popov, Dmitry A. Gavrilenko, Roman D. Pavlov, Mikhail S. Baranov, Diana E. Kaurova, Ivan N. Myasnyanko, Dmitry S. Ivanov, Vadim Yu. Balabanyan

    Introduction: Sydnonimines are a promising group of drugs for development of novel substances with predominant cerebral vasodilatory activity. One of them is experimental compound with laboratory code BBP20233. The mechanism of action of BBP2023 compound is tied to its metabolites. This study aims for identification of biotransformation products of BBP2023 using HPLC-MS/MS method. Materials and Methods: Identification of BBP2023 biotransformation products was performed in male rats and male rabbits after intragastric administration of BBP2023 in form of oil emulsion. Blood samples were collected before and 1 and 8 hours after administration. Urine samples from rats were collected before and 24 hours after administration. Additionally, complete liver isolation was performed in another group of rats to investigate liver’s role in BBP2023 metabolism. Identification of products was performed using HPLC-MS/MS method as well as UHR-TOF method. Results and Discussion: Analysis of rat plasma samples collected 1 hour after administration revealed the presence of parent compound, active metabolite SIN, geranamine and various isomers of OH-derivatives. Analysis of rat urine samples collected 24 hours after administration showed the presence of glucuronic acid conjugates of SIN and parent compound. Similar results were obtained from rabbit plasma samples, although with less variety of hydroxylated derivative isomers. Conclusion: Investigated features of BBP2023 biotransformation require detailed analysis of pharmacokinetics for both BBP2023 and its metabolites to determine their role in therapeutic effect and possible adverse effects.


  • Open Access

    Antiamnestic effect of new nicotinic acid derivatives

    by Victor V. Yasnetsov, Diana E. Kaurova, Sofia Ya. Skachilova, Evgeniy Yu. Bersenev

    Introduction: The search for new drugs for the prevention and treatment of vascular cognitive disorders continues to be a relevant task of pharmacology. In this regard, the aim of this work is to study the antiamnestic effect of five new nicotinic acid derivatives in comparison with the well-known drug mexidol (ethylmethylhydroxypyridine succinate) in animals. Materials and methods: The experiments were carried out on white male mice using conditioned passive avoidance reflex (CPAR). Electroconvulsive shock (ECS), scopolamine administration, and acute hypoxia in a hermetic chamber were used as amnesic effects. Testing for the safety of CPAR was performed 24 h after amnesic exposure. The new substances, reference drug mexidol, and a 0.9% sodium chloride solution (control group) were administered once intraperitoneally 60 min before mice training. Results and discussion: Three of the five new nicotinic acid derivatives, LKhT 4-19 (100 mg/kg), LKhT 6-19 (25, 50, and 100 mg/kg), and LKhT 7-19 (100 mg/kg), have antiamnestic properties on models of amnesia in mice induced by ESC, scopolamine, and acute hypoxia in a hermetic chamber. At the same time, the most efficient substance – LKhT 6-19 – exceeds the reference drug mexidol on all three models used. In addition, this compound is also more efficient than two other new compounds, LKhT 4-19 and LKhT 7-19, on the model of ESC-induced amnesia and LKhT 7-19 on the scopolamine-induced amnesia model. Conclusion: Compound LKhT 6-19 is promising for further advanced preclinical studies as a potential drug with antiamnestic activity.